SSKN · As filed with the SEC
STRATA Skin Sciences cash flow statement, by fiscal year
The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | (6,261) | (10,086) | (10,830) | (5,549) | (2,706) | (4,412) | (3,790) | (4,033) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||||
| Depreciation and amortization | 4,123 | 4,968 | 5,553 | 5,293 | 3,736 | 3,585 | 4,503 | 5,397 |
| Amortization of right-of-use assets | — | — | — | — | — | — | 318,000 | — |
| Impairment of goodwill | 0 | 3,861 | 2,284 | — | — | — | — | — |
| Amortization of operating lease right-of-use assets | 344 | 339 | 349 | 395 | 350 | 326 | — | — |
| Amortization of deferred financing costs and debt discount | 157 | 148 | 140 | 157 | 37 | 0 | 174 | — |
| Provision for credit losses | 129 | (182) | (110) | 107 | 1 | 90 | 43 | (30) |
| Gain on cancellation of distributor rights agreement | — | — | — | — | — | — | 0 | (11,000) |
| Impairment of lasers placed-in-service | — | — | — | — | — | 24,000 | 30,000 | 194,000 |
| Impairment of intangible assets | — | — | — | — | — | — | — | 0 |
| Stock-based compensation expense | 643 | 427 | 1,303 | 1,466 | 1,643 | 1,633 | 1,195 | 904 |
| Loss on debt extinguishment | — | 0 | 909,000 | — | — | — | — | 0 |
| Amortization of debt discount | — | — | — | — | — | — | — | 50,000 |
| Amortization of deferred financing costs | — | — | — | — | — | — | — | 107,000 |
| Change in fair value of warrant liability | — | — | — | — | — | — | — | 0 |
| Change in fair value of embedded conversion feature | — | — | — | — | — | — | — | 0 |
| Loss on disposal of property and equipment | 92 | 49 | 72 | 52 | 140 | — | 0 | 407 |
| Gain on forgiveness of debt | — | — | — | 0 | (2,029,000) | — | — | — |
| Settlement gains | (1,135) | — | — | — | — | — | — | — |
| Inventory write-off | 0 | 162 | — | — | — | — | — | — |
| Deferred income taxes | 0 | (186) | (120) | 40 | 12 | 254 | (111) | (303) |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,003 | (631) | 141 | (1,145) | (490) | 1,352 | (1,036) | (222) |
| Inventories | (288) | 572 | 689 | (1,524) | (45) | (417) | (233) | 215 |
| Prepaid expenses and other assets | (252) | (189) | 246 | (111) | (65) | 247 | 104 | (383) |
| Accounts payable | 350 | (954) | (100) | 603 | 58 | 884 | 116 | (513) |
| Accrued expenses and other liabilities | (1,248) | 2,266 | (197) | 229 | 1,679 | (444) | 634 | 1,006 |
| Other liabilities | — | — | — | — | — | (144,000) | (210,000) | (60,000) |
| Deferred revenues | (123) | (57) | (472) | (644) | (444) | (570) | 733 | 171 |
| Operating lease liabilities | — | — | — | — | (369,000) | (312,000) | (241,000) | — |
| Operating lease liabilities | (328) | (319) | (376) | (477) | — | — | — | — |
| Net cash (used in) provided by operating activities | (2,794) | 188 | (519) | (1,108) | 1,508 | 2,096 | 2,229 | 2,896 |
| Cash flows from investing activities: | ||||||||
| Lasers placed-in-service | — | — | — | — | — | (2,133,000) | (2,676,000) | (1,749,000) |
| Purchases of property and equipment | — | — | — | — | — | — | (115,000) | (13,000) |
| Payments on distributor rights liability | — | — | — | — | — | — | 0 | (23,000) |
| Purchase of property and equipment | (1,468) | (1,636) | (5,019) | (3,552) | (3,653) | (26) | — | — |
| Cash paid in connection with TheraClear asset acquisition | — | — | 0 | — | (3,473,000) | — | — | — |
| TheraClear Corporation | — | — | — | (631,000) | — | — | — | — |
| RA Medical Systems, Inc. | — | — | — | 0 | — | — | — | — |
| Net cash used in investing activities | (1,468) | (1,636) | (5,019) | (4,183) | (7,126) | (2,159) | (2,791) | (1,785) |
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of stock options | — | — | — | — | 0 | 18,000 | — | — |
| Proceeds from long-term debt | — | 0 | 7,000,000 | 0 | 8,000,000 | — | — | — |
| Payment of deferred financing costs | — | 0 | (97,000) | 0 | (133,000) | — | — | — |
| Repayment of note payable | — | — | — | 0 | (7,275,000) | — | — | (357,000) |
| Repayments of long-term debt | — | — | — | 0 | (500,000) | 0 | (7,571,000) | (3,000,000) |
| Proceeds (payments) on notes payable | — | — | — | — | — | — | 7,275,000 | — |
| Proceeds on notes payable | — | — | — | — | — | 2,528,000 | — | — |
| Payment of contingent consideration | 0 | (18) | (42) | (500) | — | — | — | — |
| Sale of common stock, net of offering costs | 3,579 | 1,943 | — | — | — | — | 0 | 17,000 |
| Offering costs | — | — | — | — | — | — | 0 | (2,336,000) |
| Net cash provided by financing activities | 3,579 | 1,925 | 6,861 | (500) | 92 | 2,546 | (296) | 11,307 |
| Effect of exchange rate changes on cash | — | — | — | — | — | — | — | 0 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (683) | 477 | 1,323 | (5,791) | (5,526) | 2,483 | (858) | 12,418 |
| Cash and cash equivalents, beginning of period | — | — | — | — | — | — | 16,487,000 | 4,069,000 |
| Cash and cash equivalents, end of period | — | — | — | — | — | — | — | 16,487,000 |
| Cash, cash equivalents and restricted cash at beginning of year | 8,595 | 8,118 | 6,795 | 12,586 | 18,112 | 15,629 | 16,487 | — |
| Cash, cash equivalents and restricted cash at end of year | 7,912 | 8,595 | 8,118 | 6,795 | 12,586 | 18,112 | 15,629 | — |
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid during the year for interest | 1,811 | 1,973 | 1,415 | 744 | 222 | 211 | 766 | 1,009 |
| Cash paid for income taxes | — | — | — | — | — | 0 | 0 | 17,000 |
| Lease liabilities from obtaining right of use assets | — | — | — | — | — | 0 | 1,632,000 | — |
| Cash paid during the year for income taxes | — | 23,000 | 22,000 | 19,000 | — | — | — | — |
| Supplemental schedule of non-cash operating, investing and financing activities: | ||||||||
| Conversion of senior secured convertible debentures into common stock | — | — | — | — | — | — | — | 0 |
| Prepaid insurance financed with notes payable | — | — | — | — | — | — | — | 0 |
| Acquisition of distributor rights asset for license liability | — | — | — | — | — | — | — | 0 |
| Issuance of convertible preferred stock in exchange for convertible debentures | — | — | — | — | — | — | — | 0 |
| Modification of common stock warrants | — | 0 | 384,000 | — | — | — | — | — |
| Transfer of property and equipment to inventories | 280 | 307 | 267 | 463 | — | — | — | — |
| Issuance of common stock warrants in connection with Senior Term Facility | — | — | — | 0 | 585,000 | — | — | — |
| Assumed deferred revenues in connection with asset acquisition | — | — | — | 0 | 1,841,000 | — | — | — |
| Change in intangible assets and fair value of contingent consideration | — | 0 | 7,374,000 | — | — | — | — | — |
| Accrued equity issuance costs included in accounts payable | 25 | — | — | — | — | — | — | — |
| Write-off of contingent consideration to settlement gains | 1,176 | — | — | — | — | — | — | — |
| Write-off of intangible assets to settlement gains | 725 | — | — | — | — | — | — | — |
| Accrued exit fee recorded as debt discount | 0 | 150 | 450 | — | — | — | — | — |
| Accrued payment of contingent consideration | 0 | 44 | 18 | — | — | — | — | — |
| Inventories acquired in connection with TheraClear asset acquisition | — | — | 0 | 71,000 | — | — | — | — |
| Intangible assets acquired in connection with TheraClear asset acquisition | — | — | 0 | 10,182,000 | — | — | — | — |
| Contingent consideration issued in connection with TheraClear asset acquisition | — | — | — | 9,122,000 | — | — | — | — |
| Contingent consideration issued in connection with TheraClear asset | — | — | 0 | — | — | — | — | — |
| Common stock issued in connection with TheraClear asset acquisition | — | — | 0 | 500,000 | — | — | — | — |
| Change in operating lease right-of-use assets and liabilities due to new and amended leases | — | — | 0 | 732,000 | — | — | — | — |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | 0 | 977 | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.